首页> 外文期刊>Medical Devices: Evidence and Research >Analysis of postmarket complaints database for the iFuse SI Joint Fusion System?: a minimally invasive treatment for degenerative sacroiliitis and sacroiliac joint disruption
【24h】

Analysis of postmarket complaints database for the iFuse SI Joint Fusion System?: a minimally invasive treatment for degenerative sacroiliitis and sacroiliac joint disruption

机译:iFuse SI关节融合系统的售后投诉数据库分析:退化性sa关节炎和sa关节破坏的微创治疗

获取原文
           

摘要

Background: The sacroiliac joint is a common but under-recognized source of low back and gluteal pain. Patients with degenerative sacroiliitis or sacroiliac joint disruption resistant to nonsurgical treatments may undergo open surgery with sacroiliac joint arthrodesis, although outcomes are mixed and risks are significant. Minimally invasive sacroiliac joint arthrodesis was developed to minimize the risk of iatrogenic injury and to improve patient outcomes compared with open surgery.Methods: Between April 2009 and January 2013, 5319 patients were treated with the iFuse SI Joint Fusion System? for conditions including sacroiliac joint disruption and degenerative sacroiliitis. A database was prospectively developed to record all complaints reported to the manufacturer in patients treated with the iFuse device. Complaints were collected through spontaneous reporting mechanisms in support of ongoing mandatory postmarket surveillance efforts.Results: Complaints were reported in 204 (3.8%) patients treated with the iFuse system. Pain was the most commonly reported clinical complaint (n = 119, 2.2%), with nerve impingement (n = 48, 0.9%) and recurrent sacroiliac joint pain (n = 43, 0.8%) most frequently cited. All other clinical complaints were rare (≤0.2%). Ninety-six revision surgeries were performed in 94 (1.8%) patients at a median follow-up of four (range 0–30) months. Revisions were typically performed in the early postoperative period for treatment of a symptomatic malpositioned implant (n = 46, 0.9%) or to correct an improperly sized implant in an asymptomatic patient (n = 10, 0.2%). Revisions in the late postoperative period were performed to treat symptom recurrence (n = 34, 0.6%) or for continued pain of undetermined etiology (n = 6, 0.1%).Conclusion: Analysis of a postmarket product complaints database demonstrates an overall low risk of complaints with the iFuse SI Joint Fusion System in patients with degenerative sacroiliitis or sacroiliac joint disruption.
机译:背景:sa关节是常见的但尚未得到充分认识的腰背和臀痛的来源。退化性sa关节炎或对非手术治疗有sa关节破坏的患者可进行open关节关节固定术,尽管结局复杂且风险显着。与开放式手术相比,微创sa关节置换术可以降低医源性损伤的风险并改善患者预后。方法:2009年4月至2013年1月之间,iFuse SI关节融合系统治疗了5319例患者。适用于sa关节破坏和变性sa炎等疾病。前瞻性地开发了一个数据库来记录使用iFuse设备治疗的患者向制造商报告的所有投诉。通过自发报告机制收集投诉,以支持正在进行的上市后强制性监督工作。结果:在使用iFuse系统治疗的204位患者中,有3.8%的患者投诉。疼痛是最常报告的临床主诉(n = 119,2.2%),神经冲击(n = 48,0.9%)和and关节复发性疼痛(n = 43,0.8%)是最常被提及的。所有其他临床症状很少见(≤0.2%)。 94例患者(1.8%)进行了96例翻修手术,平均随访4个月(0-30个月)。通常在术后早期进行翻修,以治疗有症状的植入物不当(n = 46,0.9%)或纠正无症状患者的植入物尺寸不当(n = 10,0.2%)。术后后期进行翻修以治疗症状复发(n = 34,0.6%)或病因未明(持续性疼痛)(n = 6,0.1%)。结论:售后产品投诉数据库分析表明总体风险较低iFuse SI关节融合系统对变性sa关节炎或or关节破坏患者的投诉。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号